FDA Clears Thermo Scientific EliA RNA Pol III and EliA Rib-P Tests for Use in U.S.
Retrieved on:
Thursday, June 9, 2022
FDA, Medical Devices, Other Health, Health, Genetics, Science, Applied Biosystems, Meta-analysis, Lupus, Arthritis, Research, Patheon, Autoantibody, Mayo Clinic College of Medicine and Science, SLE, Systemic scleroderma, Invitrogen, American College, Autoimmunity Reviews, Immunoglobulin G, PPD, Connective tissue, Scleroderma, FDA, Patient, Medical laboratory, RNA polymerase III, Fisher Scientific, BMC Medicine, Laboratory, Health, Review, Antibody, Diagnosis, Thermo Fisher Scientific, Autoimmunity, CTD, Efficiency, Systemic, Pharmaceutical Services Negotiating Committee, Elia, RNA polymerase, Mindful Scientific Inc., Medical device, Vaccine, Dermatology
Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).
Key Points:
- Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).
- [2] The EliA RNA Pol III test completes a criteria based EliA SSc panel and is the first fully automated RNA Polymerase test available in the U.S.
A subset of SLE patients present with monospecific Ribosomal P antibodies. - The new EliA RNA Pol III and EliA Rib-P tests have been designed to improve the differentiation of SSc and SLE from other connective tissue diseases.
- For more information on the Thermo Scientific EliA RNA Pol III and EliA Rib-P tests, please visit https://www.thermofisher.com/phadia .